EN | RU
EN | RU

Help Support

Back

Study evaluates viral clearance, mortality, and other clinical outcomes of hydroxychloroquine in COVID-19

Study evaluates viral clearance, mortality, and other clinical outcomes of hydroxychloroquine in COVID-19 Study evaluates viral clearance, mortality, and other clinical outcomes of hydroxychloroquine in COVID-19
Study evaluates viral clearance, mortality, and other clinical outcomes of hydroxychloroquine in COVID-19 Study evaluates viral clearance, mortality, and other clinical outcomes of hydroxychloroquine in COVID-19

A meta-analysis and systematic review were carried out to systematically review the efficacy and safety of hydroxychloroquine to treat or prevent coronavirus disease 2019 (COVID-19) reported by randomized controlled trials (RCTs).

See All

Key take away

Hydroxychloroquine was found to have no advantage in treating or preventing coronavirus infection. Furthermore, it was linked with a greater occurrence of adverse events.

Background

A meta-analysis and systematic review were carried out to systematically review the efficacy and safety of hydroxychloroquine to treat or prevent coronavirus disease 2019 (COVID-19) reported by randomized controlled trials (RCTs).

Method

Multiple databases and preprint servers were explored for RCTs that explored hydroxychloroquine to treat/prevent COVID-19. The impact of hydroxychloroquine on death, viral clearance, and other clinical outcomes were assessed.  About 21 RCTs (Out of 768 papers screened) with 14,138 participants were incorporated.

Result

In total, 9 inpatient and 3 outpatient RCTs evaluated death in 8,596 subjects with a pooled risk difference of 0.01. Notably, 6 studies determined viral clearance at seven days with a pooled risk ratio of 1.11 and 5 studies at 14 days with a pooled risk ratio of 0.96.

Numerous trials showed no significant effect of hydroxychloroquine on other clinical outcomes. As per five prevention RCTs with 5012 subjects, there was no effect of hydroxychloroquine on the risk of getting coronavirus infection. In total, 13 trials demonstrated that hydroxychloroquine was linked with an elevated risk of adverse events.

A high level of certainty of evidence indicated that hydroxychloroquine is not effective in lowering mortality in coronavirus-infected subjects. As per the lower certainty evidence, hydroxychloroquine neither leads to improvement in viral clearance and other clinical outcomes nor leads to prevention of coronavirus infection in individuals having elevated-risk exposure. Hydroxychloroquine was found to be linked with an elevated rate of adverse events. 

Conclusion

The use of hydroxychloroquine was associated with a greater occurrence of adverse events and yielded no benefit in COVID-19 patients.

Source:

Clinical and Translational Science

Article:

Mortality, viral clearance, and other clinical outcomes of hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Authors:

Zakariya Kashour et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: